RE:RE:RE:RE:RE:RE:Cash burn at AEZSNovo got played....
Executives at Strongbridge Biopharma must watch a lot of TV programmes about home improvement, because they have just pulled off the biotech equivalent of a real estate flip – selling Macrilen to Novo Nordisk for $182m up front just 10 months after licensing the product from Aeterna Zentaris for $24m.
https://www.evaluate.com/vantage/articles/news/deals/flipping-win-strongbridge-biopharma